Analysis of Volatile Organic Compounds in Patients With Type 1 Diabetes in Induced Hypoglycaemia With a Breath Analyser
The study, sponsored by the University of Bern, aims to explore the relationship between VOCs and blood glucose levels in Type 1 Diabetes patients during induced hypoglycaemic episodes. This research could lead to innovative non-invasive monitoring technologies for diabetes management, potentially positioning the BreathSpec® device as a novel tool in the diabetes care market. Given the increasing prevalence of diabetes globally, advancements in monitoring technologies could capture significant market interest. However, the competitive landscape includes established glucose monitoring devices and continuous glucose monitoring (CGM) systems, necessitating a clear differentiation strategy for any resultant product. The study's completion in July 2024 may provide critical data for future commercialization efforts.
Indication: Diabetes Mellitus
Modality: medical device
Target: Volatile Organic Compounds (VOCs) associated with blood glucose levels in Type 1 Diabetes patients.
Sponsor: University of Bern
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 21, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Volatile Organic Compounds (VOCs) associated with blood glucose levels in Type 1 Diabetes patients.
View original source fields
Condition raw: Diabetes Mellitus, Metabolic Disease, Glucose Metabolism Disorders, Endocrine System Diseases
Condition normalized: Diabetes Mellitus, Metabolic Disease, Glucose Metabolism Disorders, Endocrine System Diseases
Modality raw: medical device
Modality normalized: medical device
Target raw: Volatile Organic Compounds (VOCs) associated with blood glucose levels in Type 1 Diabetes patients.
Target normalized: Volatile Organic Compounds (VOCs) associated with blood glucose levels in Type 1 Diabetes patients.